Antihypertensive medication classes and the risk of dementia over a decade of follow-up.

ABSTRACT:

Introduction

Use of angiotensin II (ATII)-stimulating antihypertensive medication (AHM), including angiotensin receptor blockers (ARBs) and dihydropyridine calcium channel blockers (CCBs), has been associated with lower dementia risk. Previous studies had relatively short follow-up periods. The aim of this study is to investigate if these effects are sustained over longer periods.

Methods

This post hoc observational analysis was based on data from a dementia prevention trial (preDIVA and its observational extension), among Dutch community-dwelling older adults without prior diagnosis of dementia. Differential associations between AHM classes and incident dementia were studied after 7.0 and 10.4 years, based on the median follow-up durations of dementia cases and all particip

SUBMITTER: Schroevers JL 

PROVIDER: S-EPMC9799049 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature